当前位置： SCI文献检索 > CLINICAL THERAPEUTICS期刊下所有文献 > A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.

A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention.

Abstract：

BACKGROUND:The Lescol Intervention Prevention Study (LIPS) was a multinational randomized controlled trial that showed a 47% reduction in the relative risk of cardiac death and a 22% reduction in major adverse cardiac events (MACEs) from the routine use of fluvastatin, compared with controls, in patients undergoing percutaneous coronary intervention (PCI, defined as angioplasty with or without stents). In this study, MACEs included cardiac death, nonfatal myocardial infarction, and subsequent PCI and coronary artery bypass graft. Diabetes was the greatest risk factor for MACEs. OBJECTIVE:This study estimated the cost-effectiveness of fluvastatin when used for secondary prevention of MACEs after PCI in people with diabetes. METHODS:A post hoc subgroup analysis of patients with diabetes from the LIPS was used to estimate the effectiveness of fluvastatin in reducing myocardial infarction, revascularization, and cardiac death. A probabilistic Markov model was developed using United Kingdom resource and cost data to estimate the additional costs and quality-adjusted life-years (QALYs) gained over 10 years from the perspective of the British National Health Service. The model contained 6 health states, and the transition probabilities were derived from the LIPS data. Crossover from fluvastatin to other lipid-lowering drugs, withdrawal from fluvastatin, and the use of lipid-lowering drugs in the control group were included. RESULTS:In the subgroup of 202 patients with diabetes in the LIPS trial, 18 (15.0%) of 120 fluastatin patients and 21 (25.6%) of 82 control participants were insulin dependent (P = NS). Compared with the control group, patients treated with fluvastatin can expect to gain an additional mean (SD) of 0.196 (0.139) QALY per patient over 10 years (P < 0.001) and will cost the health service an additional mean (SD) of 10 pounds ( 448 pounds) (P = NS) (mean [SD] US $16 [$689]). The additional cost per QALY gained was 51 pounds (US $78). The key determinants of cost-effectiveness included the probabilities of repeat interventions, cardiac death, the cost of fluvastatin, and the time horizon used for the evaluation. CONCLUSION:Fluvastatin was an economically efficient treatment to prevent MACEs in these patients with diabetes undergoing PCI.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Scuffham PA,Chaplin S

doi

10.1016/j.clinthera.2005.09.012

subject

Has Abstract

pub_date

2005-09-01 00:00:00

pages

1467-77

issue

9

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(05)00177-3

journal_volume

27

pub_type

杂志文章

相关文献

CLINICAL THERAPEUTICS文献大全
  • Recent Advances in the Pathogenesis of Mucormycoses.

    abstract：PURPOSE:The purposes of this review are to describe the pathogenesis of mucormycosis and to address recent research advances in understanding the mechanisms of fungal invasion and dissemination. METHODS:Studies and reviews published in the PubMed and ClinicalTrials.gov databases until December 2017 that explored or re...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2018.03.009

    authors： Petrikkos G,Tsioutis C

    更新日期：2018-06-01 00:00:00

  • Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin.

    abstract：:This article reviews the administration, efficacy, and safety of prophylactic intravenous immunoglobulin in patients with secondary immunodeficiency and those undergoing allogeneic bone marrow transplantation. Associated infections in these immunosuppressed patients are examined as they relate to transfusion-associate...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/s0149-2918(96)80204-9

    authors： Sullivan KM

    更新日期：1996-01-01 00:00:00

  • Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.

    abstract：PURPOSE:This study was designed to evaluate the safety and pharmacokinetic profiles of MRX-I tablet, an oxazolidinone antibacterial agent, in healthy Chinese subjects. METHODS:The study was composed of 3 sequential periods. Period 1 was a randomized, double-blind, placebo-controlled, sequential ascending dose (50 to 1...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2017.12.017

    authors： Wu X,Li Y,Zhang J,Zhang Y,Yu J,Cao G,Chen Y,Guo B,Shi Y,Huang J,Cao Y,Liu X,Wu J,Gordeev MF,Yuan H,Wang W

    更新日期：2018-02-01 00:00:00

  • Trends in off-label beta-blocker use: a secondary data analysis.

    abstract：BACKGROUND:The off-label use of beta-blockers might be prevalent, but no studies have provided empiric data on the off-label use based on utilization data. OBJECTIVE:This secondary data analysis was conducted to describe the trends of off-label use of beta-blockers among ambulatory visits made to office-based physicia...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2006.10.015

    authors： Lin HW,Phan K,Lin SJ

    更新日期：2006-10-01 00:00:00

  • Results of prifinium bromide therapy in irritable bowel syndrome.

    abstract：:An open clinical trial with prifinium bromide, an anticholinergic agent, was carried out in 21 patients with irritable bowel syndrome showing clear psychosomatic characteristics. The clinical efficacy was evaluated by comparing the symptomatic severity before, during, and after treatment with prifinium bromide, 90 mg/...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Sasaki T,Takekoshi T,Okada T

    更新日期：1985-01-01 00:00:00

  • Effect of Gabapentin Enacarbil on Individual Items of the International Restless Legs Study Group Rating Scale and Post-sleep Questionnaire in Adults with Moderate-to-Severe Primary Restless Legs Syndrome: Pooled Analysis of 3 Randomized Trials.

    abstract：PURPOSE:Few studies have investigated restless legs syndrome (RLS) treatment effects on individual International RLS Study Group Rating Scale (IRLS) items. We assessed the effects of gabapentin enacarbil (GEn) on individual IRLS items and their correlation with sleep disturbances in adults with moderate-to-severe prima...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clinthera.2016.05.008

    authors： Ahmed M,Hays R,Steven Poceta J,Jaros MJ,Kim R,Shang G

    更新日期：2016-07-01 00:00:00

  • A cost-of-illness study of Lyme disease in the United States.

    abstract：:Lyme disease produces a diverse clinical picture that can include serious and potentially debilitating cardiac, neurologic, joint, and skin involvement. It is characterized in three stages--early localized (stage I), early disseminated (stage II), and late disseminated (stage III)--and medical management is highly dep...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/s0149-2918(98)80081-7

    authors： Maes E,Lecomte P,Ray N

    更新日期：1998-09-01 00:00:00

  • Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

    abstract：OBJECTIVES:The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and cl...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2008.02.012

    authors： Pellicelli AM,Barbaro G,Francavilla R,Romano M,Barbarini G,Mazzoni E,Mecenate F,Paffetti A,Barlattani A,Struglia C,Villani R,Nauri L,Nosotti L,Armignacco O,Ferri F,Camporiondo MP,Soccorsi F,Club Epatologi Ospedalieri (C

    更新日期：2008-02-01 00:00:00

  • Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.

    abstract：PURPOSE:The formulary inclusion of proton pump inhibitors (PPIs) in the government hospital health services in Qatar is not comparative or restricted. Requests to include a PPI in the formulary are typically accepted if evidence of efficacy and tolerability is presented. There are no literature reports of a PPI scoring...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2016.03.004

    authors： Al-Badriyeh D,Alabbadi I,Fahey M,Al-Khal A,Zaidan M

    更新日期：2016-05-01 00:00:00

  • Electrical Muscle Stimulation Induces an Increase of VEGFR2 on Circulating Hematopoietic Stem Cells in Patients With Diabetes.

    abstract：PURPOSE:External electric muscle stimulation (EMS) of the thigh muscles was found to reduce pain resulting from diabetic neuropathy (DN), a vascular complication of diabetes. This study investigated circulating hematopoietic stem cells (HSCs) after EMS treatment. Impaired function of HSCs and the subpopulation endothel...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2017.05.340

    authors： Hidmark A,Spanidis I,Fleming TH,Volk N,Eckstein V,Groener JB,Kopf S,Nawroth PP,Oikonomou D

    更新日期：2017-06-01 00:00:00

  • Medical Outcomes Study Short Form 36: a possible source of utilities?

    abstract：:General health-status questionnaires such as the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) are frequently used to measure health-related quality of life. The SF-36, in its current form, cannot be used to measure individuals' utilities or preferences for their health state. Recently, several inves...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/S0149-2918(00)86747-8

    authors： Meletiche DM,Doshi D,Lofland JH

    更新日期：1999-11-01 00:00:00

  • Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues.

    abstract：BACKGROUND:Insulin therapy may eventually be required to maintain glycemic control in many patients with type 2 diabetes mellitus. Premixed insulin analogues offer relatively physiologic and predictable time-action profiles and are available in more convenient delivery systems with finer needles than in the past. They ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2005.07.003

    authors： Rolla AR,Rakel RE

    更新日期：2005-08-01 00:00:00

  • Estrogen in cardiovascular disease during systemic lupus erythematosus.

    abstract：PURPOSE:Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that disproportionately affects women during their childbearing years. Cardiovascular disease is the leading cause of mortality in this patient population at an age when women often have low cardiovascular risk. Hypertension is a ma...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2014.07.021

    authors： Gilbert EL,Ryan MJ

    更新日期：2014-12-01 00:00:00

  • Cardiovascular support in preterm infants.

    abstract：BACKGROUND:Despite increasing investigation in the area of cardiovascular instability in preterm infants, huge gaps in knowledge remain. None of the current treatments for hypotension, including the use of inotropic agents, have been well studied in the preterm population, and data regarding safety and efficacy are lac...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2006.09.006

    authors： Evans JR,Lou Short B,Van Meurs K,Cheryl Sachs H

    更新日期：2006-09-01 00:00:00

  • The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.

    abstract：BACKGROUND:In the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS), intramuscular (IM) interferon beta-1a (IFNbeta-1a) delayed the development of clinically definite multiple sclerosis (CDMS) in patients with a single demyelinating event who had magnetic resonance imaging (MRI) evidence...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/s0149-2918(03)80339-9

    authors： O'Connor P,CHAMPS.

    更新日期：2003-11-01 00:00:00

  • A single-dose, randomized, two-way crossover study comparing two olanzapine tablet products in healthy adult male volunteers under fasting conditions.

    abstract：BACKGROUND:Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. OBJECTIVE:The aim of this study was to assess the bioequivalence of 2 commercial 10-mg tablet formulations of olanzapine by statistical analysis of the pharmacokinetic parameters C(max), AUC from 0 to 72 hours after dosing (A...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2009.03.008

    authors： Elshafeey AH,Elsherbiny MA,Fathallah MM

    更新日期：2009-03-01 00:00:00

  • Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.

    abstract：BACKGROUND:Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH). To improve cost-effectiveness, the development of an effective and well-tolerated generic formulation is needed. OBJE...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clinthera.2007.04.013

    authors： Tsai YS,Lan SK,Ou JH,Tzai TS

    更新日期：2007-04-01 00:00:00

  • Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

    abstract：BACKGROUND:The emergence of multidrug-resistant nosocomial pathogens, such as Pseudomonas aeruginosa and Acinetobacter baumannii, has led to the revival of the systemic use of antimicrobial agent colistin in critically ill patients, but only limited data are available to define its pharmacokinetic profile in these pati...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.clinthera.2008.01.015

    authors： Markou N,Markantonis SL,Dimitrakis E,Panidis D,Boutzouka E,Karatzas S,Rafailidis P,Apostolakos H,Baltopoulos G

    更新日期：2008-01-01 00:00:00

  • Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.

    abstract：BACKGROUND:Flexibility in the recommended dosing time for a statin may improve patient compliance. OBJECTIVE:This study was designed to compare the efficacy and tolerability of morning and evening doses of controlled-release simvastatin in Korean adults with dyslipidemia. It was carried out as a requirement to obtain ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clinthera.2013.06.020

    authors： Kim SH,Kim MK,Seo HS,Hyun MS,Han KR,Cho SW,Kim YK,Hoon Park S

    更新日期：2013-09-01 00:00:00

  • Impact of transfer from animal-source insulins to biosynthetic human insulin (rDNA E coli) in patients with diabetes mellitus.

    abstract：:Six hundred forty-eight patients (50.5% men; 49.5% women) with diabetes mellitus on animal-source insulin therapy for at least five years were studied. In this patient population, approximately 68.7% had Type I insulin-dependent diabetes mellitus and 31.3% had Type II noninsulin-dependent diabetes mellitus, nonetheles...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：

    authors： Garber AJ,Davidson JA,Krosnick A,Beaser RS,Anderson JH Jr

    更新日期：1991-09-01 00:00:00

  • In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.

    abstract：BACKGROUND:Treatment of infections caused by gram-negative bacilli is increasingly challenging because of emerging resistance. Current surveillance data are informative, but may not discern differences by infection site and clinical setting, and do not incorporate pharmacodynamic (PD) characteristics when determining s...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clinthera.2009.11.021

    authors： Eagye KJ,Kuti JL,Sutherland CA,Christensen H,Nicolau DP

    更新日期：2009-11-01 00:00:00

  • Effects of Exercise on Non-motor Symptoms in Parkinson's Disease.

    abstract：:Patients with Parkinson's disease experience disabling non-motor symptoms, including autonomic dysfunction, cognitive decline, and sleep disorders. Pharmacologic treatments for these symptoms are often ineffective or have intolerable side effects. Therefore, non-pharmacologic interventions are an attractive alternativ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2017.11.004

    authors： Amara AW,Memon AA

    更新日期：2018-01-01 00:00:00

  • Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.

    abstract：:Hydroxychloroquine (HCQ), an antimalarial agent used to treat patients with autoimmune diseases, has been shown to suppress human immunodeficiency virus type 1 (HIV-1) replication in T cells and monocytes in vitro by inhibiting posttranscriptional modification of the virus. An initial randomized, placebo-controlled cl...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/s0149-2918(97)80045-8

    authors： Sperber K,Chiang G,Chen H,Ross W,Chusid E,Gonchar M,Chow R,Liriano O

    更新日期：1997-09-01 00:00:00

  • Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer.

    abstract：BACKGROUND:Panitumumab, formerly known as ABX-EGF, was the first recombinant human immunoglobulin G2 monoclonal antibody approved by the US Food and Drug Administration for the treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine-, oxa...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2008.01.014

    authors： Wu M,Rivkin A,Pham T

    更新日期：2008-01-01 00:00:00

  • Safety Alerts: An Observational Study in Portugal.

    abstract：PURPOSE:The information that is available when marketing authorizations are approved is limited. Pharmacovigilance has an important role during the postauthorization period, and alerts published by national authorities allow health care professionals to be informed about new data on safety profiles. This study therefor...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2015.07.015

    authors： Soares S,Roque F,Teixeira Rodrigues A,Figueiras A,Herdeiro MT

    更新日期：2015-09-01 00:00:00

  • Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency depart

    abstract：BACKGROUND:According to evidence-based guidelines, the combination of inhaled corticosteroids and inhaled long-acting beta(2)-agonists in a single inhaler is recommended for patients with chronic obstructive pulmonary disease (COPD) who are experiencing exacerbations. The relative effectiveness of combination products ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2010.06.022

    authors： Blais L,Forget A,Ramachandran S

    更新日期：2010-07-01 00:00:00

  • Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

    abstract：BACKGROUND:Hypersensitivity reactions consist of a variable group of clinical findings and have been described for a wide variety of chemical compounds. OBJECTIVE:This review characterizes the clinical profile of hypersensitivity to the nucleoside reverse transcriptase inhibitor abacavir sulfate. METHODS:We performed...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/s0149-2918(01)80132-6

    authors： Hetherington S,McGuirk S,Powell G,Cutrell A,Naderer O,Spreen B,Lafon S,Pearce G,Steel H

    更新日期：2001-10-01 00:00:00

  • Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes.

    abstract：BACKGROUND:Chronic obstructive pulmonary disease (COPD) is associated with substantial morbidity and mortality. Published practice guidelines and treatment algorithms for COPD are designed to increase awareness of the problem and improve patient care; however, <40% of subjects diagnosed with COPD are receiving appropri...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章,评审

    doi：10.1016/j.clinthera.2007.10.006

    authors： Hanania NA

    更新日期：2007-10-01 00:00:00

  • Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.

    abstract：BACKGROUND:Due to the emergence of community-associated strains, the prevalence of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections has increased substantially in pediatric patients. A vancomycin AUC(0-24)/MIC index >400 best predicts treatment outcomes for invasive MRSA infection in adults. Data ...

    journal_title：Clinical therapeutics

    pub_type： 杂志文章

    doi：10.1016/j.clinthera.2010.03.005

    authors： Frymoyer A,Hersh AL,Coralic Z,Benet LZ,Joseph Guglielmo B

    更新日期：2010-03-01 00:00:00

  • Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study.

    abstract：BACKGROUND:Fenofibrate lowers serum total cholesterol and triglyceride levels while it elevates serum high-density lipoprotein cholesterol (HDL-C) level. OBJECTIVE:The aim of this study was to investigate the effects of fenofibrate on the particle size of high-density lipoprotein (HDL). METHODS:Patients with hyperlip...

    journal_title：Clinical therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1016/s0149-2918(02)80064-9

    authors： Sasaki J,Yamamoto K,Ageta M

    更新日期：2002-10-01 00:00:00